Seaport Therapeutics
PublicSeaport Therapeutics is now publicly traded
The data on this page reflects Seaport Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 10, 2026
Last Round
Series B
Oct 21, 2024
Est. Valuation at Exit
$733M
Total Funding Raised
$425M
Company Overview
Seaport Therapeutics is a biopharmaceutical company focused on developing innovative neuropsychiatric medicines that address significant patient needs while providing oral bioavailability to minimize side effects and enhance patient quality of life.
Sector
Biotech
Verticals
HealthTech
AI Layer
Non-AI
Keywords
Seaport Therapeutics Comparables
Compare Seaport Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neumora | 76% | |
| Sage Therapeutics | 76% | |
| Alto Neuroscience | 73% |
Seaport Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 10, 2026 | ||||
| Series B | Oct 21, 2024 | ||||
| Series A | Apr 9, 2024 |
Key People
Founding team and executive leadership
Seaport Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CPP Investments | Series B |
| Invus Opportunities | Series B |
| ARCH Venture Partners | Series B, Series A |
| Foresite Capital | Series B |
| T. Rowe Price | Series B |
| PureTech Health | Series B, Series A |
| Invus | Series B |
Recent news
Latest coverage and updates
- attends_eventOct 11, 2026
Seaport Therapeutics, Inc. presents GlyphAgo drug-exposure data at ECNP Congress
- attends_eventOct 11, 2026
Seaport Therapeutics, Inc. presents additional pharmacokinetic data at the 39th European College of Neuropsychopharmacology (ECNP) Congress
- is_developingOct 7, 2026
Seaport Therapeutics, Inc. is developing oral versions of treatments for major depressive disorder and generalised anxiety disorder
- receives_financingSep 22, 2026
Seaport Therapeutics, Inc. received financing of $260M in initial public offering on May 1st '26
- is_developingSep 9, 2026
Seaport Therapeutics, Inc. is developing GlyphAllo
Seaport Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access